These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [MQF-FT and MQF-UFT in gallbladder and bile duct cancer].
    Author: Sakata Y, Fukushi G, Tsushima K, Suzuki H, Kimura T, Kimura M, Tamura Y, Kishibe T, Saitoh S, Itoh T.
    Journal: Gan To Kagaku Ryoho; 1988 Sep; 15(9):2731-5. PubMed ID: 3137889.
    Abstract:
    Four patients with gallbladder cancer and two with bile duct cancer were treated with mitomycin C, carboquone, 5-fluorouracil and OK-432 (MQF-OK therapy) plus tegafur (FT) or UFT. MQF-OK therapy was administered according to our original method. FT and UFT were orally given in a dose of 600-800 mg/body/day and 300-400 mg/body/day, respectively. Three with gallbladder cancer and one with bile duct cancer showed PR. Myelosuppression was observed in all cases, but recovered in two weeks after MQF therapy. We recommend the further trial of MQF-OK therapy plus FT or UFT for gallbladder and bile duct cancer.
    [Abstract] [Full Text] [Related] [New Search]